Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
The compounding pathway does not solve the problem either
Does Exilis make you lose weight
In support, recently BPC 157 increased the survival rate of cultured enteric neurons and the proliferation rate of cultured enteric glial cells (Wang et al., 2019)
In its briefing materials, FDA staff concluded the evidence weighed against adding these peptides, citing limited proof of effectiveness, gaps in how the substances are chemically characterized, and unresolved questions about impurities and immune reactions
contraindicated in neonates